Equities research analysts predict that Inovio Pharmaceuticals, Inc. (NASDAQ:INO) will announce sales of $7.75 million for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Inovio Pharmaceuticals’ earnings. The highest sales estimate is $12.99 million and the lowest is $2.50 million. Inovio Pharmaceuticals reported sales of $8.51 million in the same quarter last year, which indicates a negative year-over-year growth rate of 8.9%. The business is scheduled to issue its next quarterly earnings report on Wednesday, March 21st.

According to Zacks, analysts expect that Inovio Pharmaceuticals will report full-year sales of $7.75 million for the current financial year, with estimates ranging from $35.90 million to $46.42 million. For the next fiscal year, analysts anticipate that the company will post sales of $17.76 million per share, with estimates ranging from $10.00 million to $22.00 million. Zacks’ sales averages are an average based on a survey of analysts that cover Inovio Pharmaceuticals.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.15). The firm had revenue of $2.60 million for the quarter, compared to analysts’ expectations of $10.27 million. Inovio Pharmaceuticals had a negative net margin of 221.55% and a negative return on equity of 72.19%. The business’s quarterly revenue was down 79.2% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.28) earnings per share.

INO has been the subject of several research analyst reports. HC Wainwright set a $13.00 price objective on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, October 6th. Citigroup initiated coverage on shares of Inovio Pharmaceuticals in a research report on Friday, October 6th. They issued a “buy” rating and a $10.00 price objective for the company. Zacks Investment Research lowered shares of Inovio Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. BidaskClub lowered shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, October 13th. Finally, Royal Bank of Canada assumed coverage on shares of Inovio Pharmaceuticals in a research report on Wednesday, October 18th. They set an “outperform” rating and a $11.00 price target for the company. Three analysts have rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $19.16.

Inovio Pharmaceuticals (NASDAQ:INO) traded up $0.21 during mid-day trading on Friday, hitting $4.46. 1,443,359 shares of the company’s stock traded hands, compared to its average volume of 1,268,153. Inovio Pharmaceuticals has a 1-year low of $4.20 and a 1-year high of $9.86.

Institutional investors have recently added to or reduced their stakes in the stock. Virginia Retirement Systems ET AL acquired a new stake in Inovio Pharmaceuticals in the 3rd quarter valued at $101,000. BlueCrest Capital Management Ltd purchased a new position in Inovio Pharmaceuticals in the 2nd quarter valued at $107,000. Neuberger Berman Group LLC purchased a new position in Inovio Pharmaceuticals in the 3rd quarter valued at $115,000. Engineers Gate Manager LP purchased a new position in Inovio Pharmaceuticals in the 3rd quarter valued at $117,000. Finally, Emerald Advisers Inc. PA lifted its holdings in Inovio Pharmaceuticals by 84.0% in the 3rd quarter. Emerald Advisers Inc. PA now owns 20,323 shares of the biopharmaceutical company’s stock valued at $129,000 after purchasing an additional 9,280 shares in the last quarter. 32.27% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/inovio-pharmaceuticals-inc-ino-expected-to-post-quarterly-sales-of-7-75-million/1762316.html.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Get a free copy of the Zacks research report on Inovio Pharmaceuticals (INO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.